Aisling Capital, Others Inject $48M Into Roka Bioscience
Life science private equity firm Aisling Capital joined OrbiMed Advisors LLC, New Enterprise Associates Inc. and Tarrant Capital IP LLC in issuing $47.5 million in Series D financing for molecular testing...To view the full article, register now.
Already a subscriber? Click here to view full article